Compare Campbell Soup Co. (CPB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs GeneDx Holdings Corp — how do they compare? Campbell Soup Co. trades at $22.43 (market cap $6.78B), while GeneDx Holdings Corp trades at $82.69 (market cap $2.44B). The key difference: Campbell Soup Co. is far larger — about 2.8× GeneDx Holdings Corp's market cap, and Campbell Soup Co. pays a 6.87% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| CPB | WGS | |
|---|---|---|
Market Cap | $6.78B | $2.44B |
Sector | Consumer Staples | Technology |
52-Week High | $34.03 | $167.51 |
52-Week Low | $20.00 | $34.51 |
Enterprise Value | $13.38B | $2.48B |
Dividend Yield | 6.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.42, down 2.73% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of $0.50, beating expectations of $0.4789, while Q4 2025 missed estimates. Revenue reached $10.25B in 2025 with a net income margin of 6.12%, though profitability metrics like ROE (3.09%) remain modest. Recent news highlights product innovation with new protein soups and leadership transitions aimed at business transformation.
The outlook for CPB is cautious with a consensus price target of $20.20 below the current price, reflecting analyst skepticism (58.62% Hold, 37.93% Sell). Opportunities include cost-saving initiatives and a sustainable ~7% dividend yield, but risks involve margin pressures, high debt levels, and competitive challenges in the packaged foods sector. Investors should weigh the dividend appeal against structural profitability concerns.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
